北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学公共卫生学院  > 期刊论文
学科主题: 公共卫生
题名:
Daclizumab for relapsing remitting multiple sclerosis
作者: Liu, Jia1; Wang, Luning1; Zhan, Si-Yan2; Xia, Yinyin3
关键词: Antibodies, Monoclonal [therapeutic use] ; Antibodies, Monoclonal, Humanized ; Immunoglobulin G [therapeutic use] ; Immuno-suppressive Agents [therapeutic use] ; Multiple Sclerosis, Relapsing-Remitting [drug therapy] ; Humans
刊名: COCHRANE DATABASE OF SYSTEMATIC REVIEWS
发表日期: 2012
DOI: 10.1002/14651858.CD008127.pub3
期: 4
收录类别: SCI
文章类型: Review
WOS标题词: Science & Technology
类目[WOS]: Medicine, General & Internal
研究领域[WOS]: General & Internal Medicine
关键词[WOS]: DIAGNOSTIC-CRITERIA ; MONOCLONAL-ANTIBODY ; IN-VIVO ; CELLS ; GUIDELINES ; THERAPY
英文摘要:

Background

The anti-CD25 treatment of daclizumab appears to be effective in patients with relapsing remitting multiple sclerosis (RRMS) as regards clinical and MRI outcomes. Moreover, there are no severe safety concerns arising from clinical testing so far.

Objectives

To assess the efficacy and safety of daclizumab for the clinical progression of patients with relapsing remitting multiple sclerosis.

Search methods

We searched the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group′s Trials Register (February 2012), MEDLINE (January 1966 to February 2012), EMBASE (January 1985 to February 2012). At the same time, we handsearched the references quoted in the identified trials reports (February 2012) from the most important neurological associations and MS Societies. Contacts with researchers participating in trials on daclizumab have been established.

Selection criteria

All randomized controlled clinical trials (RCTs) evaluating daclizumab, alone or combined with other treatments versus placebo, or any other treatment for patients with RRMS.

Data collection and analysis

Two review authors independently assessed references retrieved for possible inclusion. Disagreements regarding inclusion were resolved by consensus. We contacted study authors for additional information. We collected adverse effects information from the trials.

Main results

We identified 470 references from all electronic databases searched excluding duplicate. After screening of titles and abstracts, full papers of 10 studies were obtained and assessed for eligibility. An additional ongoing trial was found. Only one trial (230 participants) evaluating the efficacy of daclizumab versus placebo in interferon beta treated patients was included. It was judged as of high quality study. No significant difference was found in the expanded disability score changes and the annualised relapse rate comparing treated versus placebo groups. No significant difference of common adverse events was found across all the groups at the endpoint. The mean number of new or enlarged gadolinium contrast-enhancing lesions was significantly decreased in the interferon beta and high-dose daclizumab group, compared with that in the interferon beta and placebo group.

Authors′ conclusions

Daclizumab is well tolerated in combination with interferon beta treated multiple sclerosis population. Comparing with placebo, high-dose daclizumab can significantly decreased the number of new or enlarged gadolinium contrast-enhancing lesions. However, the evidence of recommendation is insufficient. More well-designed RCTs or crossover controlled trials are required to evaluate the efficacy and safety of daclizumab.

语种: 英语
项目资助者: Department of Geriatric Neurology, Chinese PLA General Hospital, China
WOS记录号: WOS:000303012500011
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/65750
Appears in Collections:北京大学公共卫生学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Chinese Peoples Liberat Army Gen Hosp, Dept Geriatr Neurol, Beijing 100853, Peoples R China
2.Peking Univ, Ctr Evidence Based Med & Clin Res, Dept Epidemiol & Biostat, Sch Publ Hlth, Beijing 100871, Peoples R China
3.China CDC, Dept Surveilance & Stat, Natl Ctr TB Control & Prevent, Beijing, Peoples R China

Recommended Citation:
Liu, Jia,Wang, Luning,Zhan, Si-Yan,et al. Daclizumab for relapsing remitting multiple sclerosis[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS,2012(4).
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Liu, Jia]'s Articles
[Wang, Luning]'s Articles
[Zhan, Si-Yan]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Liu, Jia]‘s Articles
[Wang, Luning]‘s Articles
[Zhan, Si-Yan]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace